Table 5 Parameter values of the model \({\mathrm{PKPD}}_{\mathrm{lin},\mathrm{mm}}^{6\mathrm{MP}}\) estimated with the whole and the cross-validation data set, relative standard error (RSE) of fixed effect parameters and residual unexplained variability in brackets.

From: Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia

 

\({PKPD}_{lin,mm}^{6MP}\)

\({PKPD}_{lin,mm}^{6MP}\), cross-validation

Fixed effect parameters with RSE in %

CV with 95% CI, η-Shrinkage in % and p-values

Fixed effect parameters with RSE in %

CV with 95% CI, η-Shrinkage in % and p-values

\({K}_{in}^{MTX}\)[1/day]

0.032 (1)

34 [29, 38], 29, 0.75

0.029 (2)

35 [30, 40], 34, 0.86

\({K}_{eff}^{MTX}\)[1/day]

0.019 (1)

31 [26, 35], 30, 0.77

0.018 (1)

26 [20, 31], 45, 0.72

\({V}_{mm}^{6MP}\)[µmol/L/day]

0.21 (4)

56 [46, 65], 27, 0.97

0.13 (4)

42 [34, 50], 35, 0.98

\({K}_{mm}^{6MP}\)[µmol/L]

0.14 (0.1)

-

0.046 (7)

-

\({K}_{eff}^{6MP}\)[1/day]

0.050 (2)

54 [45, 63], 29, 0.97

0.044 (2)

44 [37, 51], 33, 0.91

\(base\)[G/L]

2.17 (3)

27 [24, 31], 22, 0.68

2.08 (4)

29 [25, 32], 27, 0.78

\({k}_{tr}\)[1/day]

0.15 (2)

72 [60, 82], 35, 0.57

0.17 (3)

72 [60, 84], 46, 0.65

\({slope}^{6MP}\)[L/µmol]

0.16 (4)

81 [65, 97], 40, 0.68

0.15 (6)

93 [68, 117], 45, 0.96

Îł

0.79 (5)

11[8, 12], 49, 0.89

0.82 (10)

15 [11, 18], 58, 0.54

\(inieff\)

0.87 (22)

54 [48, 59], 20, 0.63

0.88 (29)

48 [42, 53], 27, 0.69

Residual unexplained variability

Additive, MTX

0.000018 (7)

0.000022 (8)

Proportional, MTX

0.024 (8)

0.0074 (25)

Additive, 6MP

0.024 (9)

0.020 (10)

Proportional, 6MP

0.061 (5)

0.051 (6)

Proportional, ANC

0.25 (2)

0.22 (3)

  1. Coefficients of variation (CV) are calculated as \(\sqrt{\mathrm{exp}({\upomega }^{2})-1}\) with \({\upomega }^{2}\) as the variance of the interindividual variability estimated by NONMEM, and the 95% CI being calculated accordingly.